These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 34073147)

  • 1. PARP Inhibitors Talazoparib and Niraparib Sensitize Melanoma Cells to Ionizing Radiation.
    Jonuscheit S; Jost T; Gajdošová F; Wrobel M; Hecht M; Fietkau R; Distel L
    Genes (Basel); 2021 May; 12(6):. PubMed ID: 34073147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PARP inhibitors combined with ionizing radiation induce different effects in melanoma cells and healthy fibroblasts.
    Weigert V; Jost T; Hecht M; Knippertz I; Heinzerling L; Fietkau R; Distel LV
    BMC Cancer; 2020 Aug; 20(1):775. PubMed ID: 32811446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effective Radiosensitization of HNSCC Cell Lines by DNA-PKcs Inhibitor AZD7648 and PARP Inhibitors Talazoparib and Niraparib.
    Mentzel J; Hildebrand LS; Kuhlmann L; Fietkau R; Distel LV
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma.
    Chornenkyy Y; Agnihotri S; Yu M; Buczkowicz P; Rakopoulos P; Golbourn B; Garzia L; Siddaway R; Leung S; Rutka JT; Taylor MD; Dirks PB; Hawkins C
    Mol Cancer Ther; 2015 Nov; 14(11):2560-8. PubMed ID: 26351319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors.
    Hopkins TA; Shi Y; Rodriguez LE; Solomon LR; Donawho CK; DiGiammarino EL; Panchal SC; Wilsbacher JL; Gao W; Olson AM; Stolarik DF; Osterling DJ; Johnson EF; Maag D
    Mol Cancer Res; 2015 Nov; 13(11):1465-77. PubMed ID: 26217019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors.
    Thorsell AG; Ekblad T; Karlberg T; Löw M; Pinto AF; Trésaugues L; Moche M; Cohen MS; Schüler H
    J Med Chem; 2017 Feb; 60(4):1262-1271. PubMed ID: 28001384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models.
    Santiago-O'Farrill JM; Weroha SJ; Hou X; Oberg AL; Heinzen EP; Maurer MJ; Pang L; Rask P; Amaravadi RK; Becker SE; Romero I; Rubio MJ; Matias-Guiu X; Santacana M; Llombart-Cussac A; Poveda A; Lu Z; Bast RC
    Cancer; 2020 Feb; 126(4):894-907. PubMed ID: 31714594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dissecting the molecular determinants of clinical PARP1 inhibitor selectivity for tankyrase1.
    Ryan K; Bolaňos B; Smith M; Palde PB; Cuenca PD; VanArsdale TL; Niessen S; Zhang L; Behenna D; Ornelas MA; Tran KT; Kaiser S; Lum L; Stewart A; Gajiwala KS
    J Biol Chem; 2021; 296():100251. PubMed ID: 33361107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PARP inhibitors affect growth, survival and radiation susceptibility of human alveolar and embryonal rhabdomyosarcoma cell lines.
    Camero S; Ceccarelli S; De Felice F; Marampon F; Mannarino O; Camicia L; Vescarelli E; Pontecorvi P; Pizer B; Shukla R; Schiavetti A; Mollace MG; Pizzuti A; Tombolini V; Marchese C; Megiorni F; Dominici C
    J Cancer Res Clin Oncol; 2019 Jan; 145(1):137-152. PubMed ID: 30357520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Talazoparib Is a Potent Radiosensitizer in Small Cell Lung Cancer Cell Lines and Xenografts.
    Laird JH; Lok BH; Ma J; Bell A; de Stanchina E; Poirier JT; Rudin CM
    Clin Cancer Res; 2018 Oct; 24(20):5143-5152. PubMed ID: 29945991
    [No Abstract]   [Full Text] [Related]  

  • 11. Human mass balance study and metabolite profiling of
    van Andel L; Zhang Z; Lu S; Kansra V; Agarwal S; Hughes L; Tibben MM; Gebretensae A; Lucas L; Hillebrand MJX; Rosing H; Schellens JHM; Beijnen JH
    Invest New Drugs; 2017 Dec; 35(6):751-765. PubMed ID: 28303528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Common and unique genetic interactions of the poly(ADP-ribose) polymerases PARP1 and PARP2 with DNA double-strand break repair pathways.
    Ghosh R; Roy S; Kamyab J; Danzter F; Franco S
    DNA Repair (Amst); 2016 Sep; 45():56-62. PubMed ID: 27373144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular signatures of BRCAness analysis identifies PARP inhibitor Niraparib as a novel targeted therapeutic strategy for soft tissue Sarcomas.
    Li H; Tu J; Zhao Z; Chen L; Qu Y; Li H; Yao H; Wang X; Lee DF; Shen J; Wen L; Huang G; Xie X
    Theranostics; 2020; 10(21):9477-9494. PubMed ID: 32863940
    [No Abstract]   [Full Text] [Related]  

  • 14. Targeting DNA damage response in head and neck cancers through abrogation of cell cycle checkpoints.
    Molkentine JM; Molkentine DP; Bridges KA; Xie T; Yang L; Sheth A; Heffernan TP; Clump DA; Faust AZ; Ferris RL; Myers JN; Frederick MJ; Mason KA; Meyn RE; Pickering CR; Skinner HD
    Int J Radiat Biol; 2021; 97(8):1121-1128. PubMed ID: 32073931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond.
    Boussios S; Abson C; Moschetta M; Rassy E; Karathanasi A; Bhat T; Ghumman F; Sheriff M; Pavlidis N
    Drugs R D; 2020 Jun; 20(2):55-73. PubMed ID: 32215876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Niraparib (MK-4827), a novel poly(ADP-Ribose) polymerase inhibitor, radiosensitizes human lung and breast cancer cells.
    Bridges KA; Toniatti C; Buser CA; Liu H; Buchholz TA; Meyn RE
    Oncotarget; 2014 Jul; 5(13):5076-86. PubMed ID: 24970803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poly(ADP-ribose) polymerase inhibitors activate the p53 signaling pathway in neural stem/progenitor cells.
    Okuda A; Kurokawa S; Takehashi M; Maeda A; Fukuda K; Kubo Y; Nogusa H; Takatani-Nakase T; Okuda S; Ueda K; Tanaka S
    BMC Neurosci; 2017 Jan; 18(1):14. PubMed ID: 28095779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Positron-Emission Tomographic Imaging of a Fluorine 18-Radiolabeled Poly(ADP-Ribose) Polymerase 1 Inhibitor Monitors the Therapeutic Efficacy of Talazoparib in SCLC Patient-Derived Xenografts.
    Laird J; Lok BH; Carney B; Kossatz S; de Stanchina E; Reiner T; Poirier JT; Rudin CM
    J Thorac Oncol; 2019 Oct; 14(10):1743-1752. PubMed ID: 31195178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
    Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
    Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Niraparib Shows Superior Tissue Distribution and Efficacy in a Prostate Cancer Bone Metastasis Model Compared with Other PARP Inhibitors.
    Snyder LA; Damle R; Patel S; Bohrer J; Fiorella A; Driscoll J; Hawkins R; Stratton CF; Manning CD; Tatikola K; Tryputsen V; Packman K; Mamidi RNVS
    Mol Cancer Ther; 2022 Jul; 21(7):1115-1124. PubMed ID: 35499386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.